Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8A



Intermediate 1
Intermediate 2
Intermediate 3
Intermediate 4

Fig. 8B



Intermediate 5
Intermediate 6
Intermediate 7
GalNAc
GalNAc
GalNAc

Fig. 9A



HepG2 – toxicity (ASGPR1+/CD71+)
Relative cell viability (Untr. = 100%)
125
100
75
50
25
0
1
10
100
1000
10000
100000
GalNAc/GalNAc-SO1861/SO1861/GalNAc-dendron(SO1861) (nM)

Fig. 9B



Huh7 – toxicity (ASGPR1+/-/CD71+)
Relative cell viability (Untr. = 100%)
125
100
75
50
25
0
1
10
100
1000
10000
100000
GalNAc/GalNAc-SO1861/SO1861/GalNAc-dendron(SO1861) (nM)
(GalNAc)3
SO1861-EMCH
GalNAc-SO1861
(GalNAc)3-SO1861

Fig. 10A




Fig. 10B




Fig. 11A




Fig. 11B




Fig. 12A




Fig. 12B




Fig. 13A




Fig. 13B




Fig. 14A




Fig. 14B




Fig. 15A




Fig. 15B




Fig. 16A




Fig. 16B




Fig. 17A




Fig. 17B




Fig. 18A




Fig. 18B




Fig. 19A




Fig. 19B




Fig. 20



Mouse Primary Hepatocytes
Relative ApoB100 expression (Untr. = 100%)
125
100
75
50
25
0
0,000001
0,0001
0,01
1
100
10000
ApoB#02 (nM)
ApoB#02
(GalNAc)3-ApoB#02
(GalNAc)3-ApoB#02 + 2000 nM SO1861-EMCH

Fig. 21




Fig. 22





Fig. 23


(GalNAc)3-Ls-BNA
thiol-13-Apo B BNA
GalNAc
GalNAc
GalNAc
thiol-13-Apo B BNA
GalNAc
GalNAc
GalNAc